Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells

Stem Cells

Volumn 32, Issue 11, 2014, Pages 2845-2857

  Krishnamurthy, Sudha ^a   Warner, Kristy A ^a   Dong, Zhihong ^a   Imai, Atsushi ^a   Nör, Carolina ^a   Ward, Brent B ^a   Helman, Joseph I ^a   Taichman, Russell S ^a   Bellile, Emily L ^b   McCauley, Laurie K ^a,c   Polverini, Peter J ^a,c   Prince, Mark E ^c   Wicha, Max S ^c   Nör, Jacques E ^a,c,d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Perivascular niche; Self renewal; Squamous cell carcinoma; Survival

Indexed keywords

IL6 PROTEIN, HUMAN; INTERLEUKIN-6; STAT3 PROTEIN, MOUSE; STAT3 TRANSCRIPTION FACTOR;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CYTOLOGY; ENDOTHELIAL CELLS; HEAD AND NECK NEOPLASMS; HUMANS; METABOLISM; MICE; NEOPLASTIC STEM CELLS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL CELLS; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; MICE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84907887777     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1793     Document Type: Article

References (52)

1. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978.
2. Hermann PC, Bhaskar S, Cioffi M, et al. Cancer stem cells in solid tumors. Semin Cancer Biol 2010; 20: 77-84.
3. Al-Swiahb JN, Chen CH, Chuang HC, et al. Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 2010; 6: 837-850.
4. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010; 46: 158-165.
5. Kakarala M, Wicha MS,. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008: 26: 2813-2820.
6. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
7. Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
8. Krishnamurthy S, Dong Z, Vodopyanov D, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010; 70: 9969-9978.
9. Ghajar CM, Peinado H, Mori H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-817.
10. Parmar A, Marz S, Rushton S, et al. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against First-generation FLT3 Tyrosine kinase inhibitors. Cancer Res 2011; 71: 4696-4706.
11. Shen Q, Goderie SK, Jin L, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004; 304: 1338-1340.
12. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
13. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
14. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108: 3749-3754.
15. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
16. Riedel F, Zaiss I, Herzog D, et al. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005; 25: 2761-2765.
17. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113: 750-757.
18. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-4232.
19. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 4138-4143.
20. Chen YW, Chen KH, Huang PI, et al. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44(+)ALDH1(+)cells. Mol Cancer Ther 2010; 11: 2879-2892.
21. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002.
22. Wang H, Lathia JD, Wu Q, et al. Targeting interleukin-6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009; 27: 2393-2404.
23. Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
24. Makõ V, Czúcz, J, Weiszhár, Z, et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A 2010; 77: 962-970.
25. Krishnamurthy S, Nör JE,. Orosphere assay: A method for propagation of head and neck cancer stem cells. Head Neck 2013; 35: 1015-1021.
26. Nör JE, Peters MC, Christensen JB, et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001: 81: 453-463.
27. Shinriki S, Jono H, Ota K, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009; 15: 5426-5434.
28. Dai J, Lin D, Zhang J, et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 2000; 106: 887-895.
29. Kaneko T, Okiji T, Kaneko R, et al. Laser-capture microdissection for factor VIII-expressing endothelial cells in cancer tissues. Methods Mol Biol 2011; 755: 395-403.
30. Neumeister V, Agarwal S, Bordeaux J, et al. In situ identification of putative stem cells by multiplexing ALDH1, CD44 and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010; 176: 2131-2138.
31. Biddle A, Liang X, Gammon L, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71: 5317-5326.
32. Niwa H, Burdon T, Chambers I, et al. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 1998; 12: 2048-2060.
33. Matthews JR, Sansom OJ, Clarke AR,. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ 2011; 18: 1934-1943.
34. Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011; 19: 498-511.
35. Lin HY, Tsai CC, Chen LL, et al. Fibronectin and laminin promote differentiation of human mesenchymal stem cells into insulin producing cells through activating Akt and ERK. J Biomed Sci 2010; 17: 56.
36. Kim EK, Lim S, Park JM, et al. Human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by AMP-activated protein kinase. J Cell Physiol 2012; 227: 1680-1687.
37. Forastiere AA,. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 2008; 97: 701-707.
38. Sano D, Myers JN,. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007; 26: 645-662.
39. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
40. Gilbert LA, Hemann MT,. DNA-damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-366.
41. Franses JW, Baker AB, Chitalia VC, et al. Stromal endothelial cells directly influence cancer progression. Sci Transl Med 2011; 3: 66ra5.
42. Gõmez-Gaviro MV, Lovell-Badge R, Fernández-Avilés F, et al. The vascular stem cell niche. J Cardiovas Transl Res 2012; 5: 618-630.
43. Makõ V, Czúcz J, Weiszhár Z, et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A 2010; 77: 962-970.
44. Neiva KG, Zhang Z, Miyazawa M, et al. Crosstalk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009; 11: 583-593.
45. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010; 120: 485-497.
46. Hwang WL, Yang MH, Tsai ML, et al. SNAIL regulates Interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011; 141: 279-291.
47. Zhang Z, Dong Z, Lauxen IS, et al. Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res 2014; 74: 2869-2881.
48. Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28: 2940-2947.
49. Tanaka T, Ogata A, Narazaki M,. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010; 6: 843-854.
50. Rossi JF, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010; 103: 1154-1162.
51. Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490.
52. Neiva KG, Warner KA, Campos MS, et al. Endothelial cell-derived interleukin-6 regulates tumor growth. BMC Cancer 2014; 14: 99.